Dupont Capital Management Corp Akebia Therapeutics, Inc. Transaction History

Dupont Capital Management Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 30, 2021	SELL	$2.83 - $4.2 $205,087 - $304,369	-72,469 Closed	0 $0
Q1 2021 Apr 29, 2021	SELL	$2.92 - $5.06 $43,397 - $75,201	-14,862 Reduced 17.02%	72,469 $245,000
Q4 2020 Jan 28, 2021	SELL	$2.22 - $3.78 $14,469 - $24,638	-6,518 Reduced 6.95%	87,331 $245,000
Q3 2020 Oct 29, 2020	BUY	$2.39 - $13.08 $142,470 - $779,711	59,611 Added 174.11%	93,849 $236,000
Q2 2020 Jul 24, 2020	SELL	$6.67 - $13.58 $20,390 - $41,514	-3,057 Reduced 8.2%	34,238 $465,000
Q1 2020 Apr 29, 2020	BUY	$4.1 - $10.24 $152,909 - $381,900	37,295 New	37,295 $283,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $346M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.